APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Zhejiang Taimei Medical Technology Co Ltd / Equity Capital Markets

Zhejiang Taimei Medical Technology Co Ltd (1482194D CH)

Zhejiang Taimei Medical Technology Co Ltd

<ul>
<li>
<a href="https://www.smartkarma.com/entities/zhejiang-taimei-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:40859:1" rel="noopener">Zhejiang Taimei Medical Technology Co Ltd (1482194D CH)</a> is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley and CICC.</li>
<li>Zhejiang Taimei Medical Technology (ZTMT) is a digital solution provider for the life sciences R&amp;D and commercialization sector.</li>
<li>As per the CIC report in the application proof, the firm was the largest digital solution provider for life sciences R&amp;D and commercialization in China in terms of 2022 revenue.</li>
</ul>



Zhejiang Taimei Medical Technology Co Ltd (1482194D CH) is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley and CICC.
Zhejiang Taimei Medical Technology (ZTMT) is a digital solution provider for the life sciences R&amp;D and commercialization sector.
As per the CIC report in the application proof, the firm was the largest digital solution provider for life sciences R&amp;D and commercialization in China in terms of 2022 revenue.


Zhejiang Taimei Medical Technology Pre-IPO Tearsheet